



## Cancer Vaccines 3.0

Guest Editor:

**Dr. So Young Yoo**  
BIO-IT Foundry Technology  
Institute, Pusan National  
University, Busan, Republic of  
Korea

Deadline for manuscript  
submissions:

**closed (31 January 2025)**

### Message from the Guest Editor

Dear Colleagues,

Vaccines have saved millions of people from infectious diseases. Despite advances in immunology and medicine, developing vaccines against cancers is still a challenge for researchers. Recent studies have shown some remarkable steps toward successful development. Vaccines are used to induce antitumor immunity through specific tumor-associated antigens. Cancer cells also express normal cell antigens, which limits the development of therapeutic vaccines. Targeting tumor-associated antigens and neoantigens on cancer cells is widely used to stimulate effective antitumor immunity in therapeutic vaccine approaches. In order to target the tumor microenvironment, combined therapeutic approaches using oncolytic viruses, immune checkpoint inhibitors, and adoptive T-cells therapy have been widely employed. This Special Issue will specially focus on cancer vaccine development. Therefore, we welcome research articles as well as review articles, which would not only provide immense knowledge in these topics but also lead to new directions in cancer vaccine research.

Dr. So Young Yoo  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ger Rijkers

Department of Health, Cognition  
and Behavior, University College  
Roosevelt, 4331 CB Middelburg,  
The Netherlands

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

Vaccines Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)